key: cord-1049143-ismkry9r authors: Selhorst, Philippe; Van Ierssel, Sabrina; Michiels, Jo; Mariën, Joachim; Bartholomeeusen, Koen; Dirinck, Eveline; Vandamme, Sarah; Jansens, Hilde; Ariën, Kevin K title: Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response date: 2020-12-14 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1850 sha: f991f0d74eae8baf74b40b0700fc3c8330b7380e doc_id: 1049143 cord_uid: ismkry9r BACKGROUND: It is currently unclear whether SARS-CoV-2 reinfection will remain a rare event, only occurring in individuals who fail to mount an effective immune response, or whether it will occur more frequently when humoral immunity wanes following primary infection. METHODS: A case of reinfection was observed in a Belgian nosocomial outbreak involving 3 patients and 2 health care workers. To distinguish reinfection from persistent infection and detect potential transmission clusters, whole genome sequencing was performed on nasopharyngeal swabs of all individuals including the reinfection case’s first episode. IgA, IgM, and IgG and neutralizing antibody responses were quantified in serum of all individuals, and viral infectiousness was measured in the swabs of the reinfection case. RESULTS: Reinfection was confirmed in a young, immunocompetent health care worker as viral genomes derived from the first and second episode belonged to different SARS-CoV-2 clades. The symptomatic reinfection occurred after an interval of 185 days, despite the development of an effective humoral immune response following symptomatic primary infection. The second episode, however, was milder and characterized by a fast rise in serum IgG and neutralizing antibodies. Although contact tracing and virus culture remained inconclusive, the health care worker formed a transmission cluster with 3 patients and showed evidence of virus replication but not of neutralizing antibodies in her nasopharyngeal swabs. CONCLUSION: If this case is representative of most Covid-19 patients, long-lived protective immunity against SARS-CoV-2 after primary infection might not be likely. The mechanism, extent, and duration by which primary SARS-CoV-2 infection provides immunity against reinfection are currently unclear. For common cold coronaviruses, loss of immunity and reinfection with the same virus have been reported to occur frequently 12 months after primary infection [1] . For SARS-CoV-2, persistent viral shedding can occur over prolonged periods of time following clinical recovery [2] . To confirm genuine reinfection, whole-genome sequencing is required. Since the start of the SARS-CoV-2 pandemic 11 months ago, only 8 published and confirmed cases of reinfection were reported in Hong Kong [3] , the USA [4, 5] , Belgium [6] , the Netherlands [7] , Ecuador [8] , and India [9] . These cases likely are an underestimate due to the limited detection of asymptomatic cases. In fact many more cases were reported in the media and on preprint servers [2, [10] [11] [12] . Hence, it remains to be seen whether these reinfection cases represent the tail end of the distribution with many more to come or whether SARS-CoV-2 reinfection remains a rare event. One hypothesis could be that reinfections occurs as a result of immune evasion by another variant of SARS-CoV-2. However, the genomic variation seen across SARS-CoV-2 sequences are limited and likely the result of neutral evolution, rather than adaptive selection, and although the D614G mutation in spike has become consensus, there is no evidence that this mutation is linked to host immune pressure [13, 14] . Another hypothesis could be that these reinfections only occur in individuals who do not develop an effective immune response during primary infection. Indeed, not all Covid-19 patients seroconvert [15, 16] and not all who seroconvert develop neutralizing antibodies [17] . Furthermore, disease severity seems to correlate with higher IgG [18] [19] [20] and neutralizing antibody titers [19, 20] . Unfortunately, in only two of all reported reinfection cases antibody testing was reported after the first episode. In the Hong Kong case, IgGs but no neutralizing antibodies were detected 10 and 43 days post-symptom onset (pso) [3, 21] whereas in the Ecuador case, IgMs but no IgGs were detected M a n u s c r i p t 5 by rapid test 4 days pso [8] . Neutralizing antibodies were not measured. Hence, it is currently unclear whether these reinfection cases were able to mount an effective immune response after primary infection. Finally, it is not known whether immunity prevents onward transmission from those who are reinfected. Most reported reinfection cases [3, 4, [6] [7] [8] 11] showed nasopharyngeal samples with high RT-qPCR Ct values, from which virus is usually unculturable. Five Indian health care workers however, displayed high viral loads during their secondary infection but no viral culture was performed to determine the infectiousness of their virus [9, 12] . Here we describe a case of symptomatic reinfection in a health care worker despite having developed a neutralizing antibody response following symptomatic primary infection. The reinfection occurred with an interval of 185 days during a nosocomial outbreak involving 5 individuals. Whole genome sequencing was performed, and humoral immune responses and viral infectiousness were quantified. Sample collection and clinical evaluation were performed in view of diagnosis and standard of care and approved by the hospital's ethical committee (EC/PM/nvb/2020.084). Oral consent was obtained from all patients before sampling followed by written consent prior to publication. Initial SARS-CoV-2 diagnosis was performed at the hospital on nasopharyngeal swabs using the Xpert Xpress SARS-CoV-2 test on the GeneXpert® Platform (Cepheid, USA) as per manufacturer's instructions or by in-house PCR [22] with extraction on NucliSens EasyMag® (Biomérieux, France) and amplification on Cobas LightCycler® (Roche, Switzerland). Complete blood counts were performed on XN-9100® (Sysmex) and biochemistry parameters on Atellica® (Siemens, Germany). A c c e p t e d M a n u s c r i p t 6 At the Institute of Tropical Medicine Antwerp, RNA was extracted from UTM or eSwab medium after inactivation at 56°C with proteinase K using a Maxwell RSC Instrument. RNA from phocine distemper virus was added to all samples as an internal extraction and PCR inhibition control [23] . A SARS-CoV-2-specific RT-qPCR was then performed to amplify a 112 bp fragment of the E gene as previously described [22] with 5 µL RNA in a 25 µL reaction using the Bioline SensiFAST mix, Reverse Transcriptase and RiboSafe RNase inhibitor. To determine the presence of SARS-CoV-2 replicase activity, a negative strand RT-qPCR was performed as previously described [24] with FWD-Tagprimer-1 (catacgcacggataaa-GCAAGAGATGGTTGTGTTCCC), Tag-primer-1 (catacgcacggataaa), REVprimer-1 (GTAAATGTTGTACCATCACACG) and FAM-labeled negative-strand-probe-1 (CAGCAGCCAAACTAATGGTTGTCATA). Whole genome sequencing was performed on an Oxford Nanopore MinION device using R9.4 flow cells (Oxford Nanopore Technologies, UK) after a multiplex PCR with an 800bp SARS-CoV-2 primer scheme as previously described [25] . Sequence reads were basecalled in high accuracy mode and demultiplexed using the Guppy algorithm v3.6. Reads were aligned to the reference genome The Elecsys electrochemiluminescence immunoassay on the Cobas 8000® analyzer (Roche A c c e p t e d M a n u s c r i p t 8 In September 2020, a nosocomial outbreak occurred at an internal medicine ward in a Belgian reported to confer resistance to convalescent plasma or RBD-specific monoclonal antibodies [28] . Finally, the viral sequence derived from HCW2 differed by 27 nucleotides from HCW1's virus and belonged to GISAID's GH clade (Figure 1 and 2 ). This suggests that HCW2 was infected by an external transmission source which corresponds with the fact that her partner also tested positive for SARS- subsample of publicly available SARS-CoV-2 genomes, we performed a blast search to include the A c c e p t e d M a n u s c r i p t 10 most closely related known sequences in our analysis. As expected, the genomes from HCW1, PAT13, and HCW2 in September were closely related to Belgian sequences obtained in July-September whereas the virus from HCW1's March episode was identical to Belgian sequences collected in that same month (Supplementary figure 1) . We then measured the presence of total SARS-CoV-2 specific antibodies as well as individual IgA, (Table 1 and Figure 3 ). No neutralizing antibodies were detected in any of the nasopharyngeal swabs including those of HCW1 taken at day 0 and day 7 pso. How transmission exactly occurred within this cluster of 4 individuals as well as its origin remain unclear. The identical genomes and timelines would suggest one index patient who infected the others. All 3 patients tested negative for SARS-CoV-2 upon admission to the hospital with a diabetic foot problem 4 to 6 weeks prior to this outbreak (Table 1) . They were put on compulsory bed rest, stayed in private rooms, and only received a maximum of 1 visitor a day as per hospital rules. Visitors, patients, and staff wore cloth/surgical masks as per hospital policy and aerosol generating procedures were performed in full PPE. It is unlikely that HCW1 contracted the virus and transmitted it to the 3 patients as HCW1 developed symptoms 4 days after PAT1 and did not nurse PAT1. One explanation could be that an asymptomatic visitor of PAT1 infected both PAT1 and HCW1 who then transmitted the virus while nursing PAT2 and PAT3 ( Figure 3 ). However, none of the close contacts of HCW1, PAT1, and PAT3 tested positive for SARS-CoV-2, although cases could have been missed. PAT2 reported symptomatic SARS-CoV-2 infection in one of her daughters 2 days after her mother's diagnosis, but is unlikely to be the index patient (and rather infected her daughter) as PAT2 developed symptoms 3 days after PAT1 who she did not have contact with. Finally, nasopharyngeal swabs taken from HCW1 at diagnosis and 6 days later showed high viral loads (Avg Ct 19 and 25 respectively), but lower than at diagnosis of primary infection (Avg Ct 13), and contained replicating virus as indicated by RT-qPCR for negative strand RNA (Avg Ct 25.5 and 28.5 respectively). Yet, we were unable to culture virus from these swabs, but this might be because we had to dilute the otherwise cytotoxic swab medium to a level where virus isolation can fail. A c c e p t e d M a n u s c r i p t 12 One of the key questions in understanding SARS-CoV-2 immunity and predicting the course of the pandemic is for how long and how frequently primary infection protects against reinfection. Eight cases of reinfection have now been described showing intervals between episodes from 48 to 142 days. In this study, we describe another genuine case of SARS-CoV-2 reinfection with an interval of 185 days. The viral genomes from the first and second episode belonged to different SARS-CoV-2 clades and phylogenomic analysis showed that the closest relatives to these 2 genomes were strains collected mostly from Belgium around the same period. We then quantified the humoral immune response in HCW1 after her first and second SARS-CoV-2 episode as it was suggested that asymptomatic and mild primary infections might not protect against reinfection. The fact that HCW1 fully seroconverted and even had significant levels of serum neutralizing antibodies 3 months after primary infection, suggests that she wasn't an exceptional patient unable to mount a humoral immune response. The re-infecting virus also didn't harbor any known spike mutations that could have enabled escape from neutralizing antibodies induced during primary infection. The durability of the humoral immune response on the other hand, remains a debated issue. Although some early studies reported a rapid loss of humoral immunity [14, 30] within 2-3 months in up to 40% of patients with mild disease [18] , more recent evidence shows that neutralizing antibodies and IgGs actually reach a stable nadir after an initial decline [20, 31] , which persists for at least 5 to 7 months, presumably as short-lived plasma cells are replaced with longlived antibody secreting cells [20] . However, as no blood sample was taken from HCW1 right before or at day 0 of the second episode, we could not reliably determine whether neutralizing antibodies persisted or whether a further loss allowed for the reinfection. Of note, neutralizing antibodies are only a marker of immunity and the antibody level needed to confer protection to SARS-CoV-2 is currently unknown. A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Seasonal coronavirus protective immunity is short-lasting Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting COVID-19 re-infection by a phylogenetically distinct SARScoronavirus-2 strain confirmed by whole genome sequencing Genomic evidence for reinfection with SARS-CoV-2: a case study A case of early re-infection with SARS-CoV-2 Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report COVID-19 Re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America Asymptomatic reinfection in two healthcare workers from 16 India with genetically distinct SARS-CoV-2 Reinfection with SARS-CoV-2 and failure of humoral immunity: a case report Whole genome sequencing confirmed SARS-CoV-2 reinfections among healthcare workers in India with increased severity in the second episode A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: a prospective longitudinal study Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Convergent antibody responses to SARS-CoV-2 in convalescent individuals Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients Orthogonal SARS-CoV-2 serological assays enable surveillance of low prevalence communities and reveal durable humoral immunity Serologic responses in healthy adult with SARS-CoV-2 reinfection Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR The development of a qualitative real-time RT-PCR assay for the detection of hepatitis C virus Detection of Zika virus replication in human semen by reverse-transcription polymerase chain reaction targeting of antisense ribonucleic acid Study of a SARS-CoV-2 outbreak in a Belgian Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Nextstrain: real-time tracking of pathogen evolution Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19 Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients A c c e p t e d M a n u s c r i p t